文献速递肝病

每日阿司匹林使用与非酒精性脂肪性肝病纤维化进展风险降低相关

Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-05-09

前瞻性队列纳入361例活检确诊的非酒精性脂肪性肝病(NAFLD)成人,2006至2015年每3至12个月随访。每日阿司匹林使用与脂肪性肝炎(NASH)和纤维化患病率较低相关,并与进展至晚期纤维化风险降低相关,且呈持续时间依赖性;非阿司匹林非甾体抗炎药(NSAID)使用与晚期纤维化风险无关。

要点

  • 每日阿司匹林使用与NASH患病几率较低相关(校正OR 0.68,95%CI 0.37-0.89)。
  • 每日阿司匹林使用与纤维化患病几率较低相关(校正OR 0.54,95%CI 0.31-0.82)。
  • 基线F0-F2纤维化者中,每日阿司匹林使用与进展至晚期纤维化风险较低相关(aHR 0.63,95%CI 0.43-0.85)。

核心结论

  • 在活检证实的NAFLD患者的前瞻性研究中,每日阿司匹林使用与NAFLD和NASH组织学特征较轻及随时间进展至晚期纤维化风险较低相关。

研究设计与样本

  • 前瞻性队列研究,纳入361例活检确诊的NAFLD成人,2006年至2015年每3至12个月随访,基线肝活检由盲法病理学家进行组织学分析。

主要发现

  • 入组时151例每日使用阿司匹林;与不规律使用相比,每日阿司匹林使用与NASH患病几率较低相关(校正OR 0.68,95%CI 0.37-0.89)及纤维化患病几率较低相关(校正OR 0.54,95%CI 0.31-0.82)。
  • 基线F0-F2纤维化者(n=317)中,86例在3692人年间进展为晚期纤维化;每日阿司匹林使用者进展至晚期纤维化风险显著低于不规律使用者(aHR 0.63,95%CI 0.43-0.85)。
  • 该关系呈持续时间依赖性(校正P趋势=0.026),使用阿司匹林至少4年或以上获益最大(aHR 0.50,95%CI 0.35-0.73)。
  • 非阿司匹林NSAID使用与晚期纤维化风险无关(aHR 0.93,95%CI 0.81-1.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: We performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3-12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression. RESULTS: At enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37-0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31-0.82). Among individuals with baseline F0-F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43-0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35-0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81-1.05). CONCLUSIONS: In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Simon TG, Henson J, Osganian S, et al. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31077838. doi:10.1016/j.cgh.2019.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。